Funda Meric-Bernstam describes how ADCs have improved over recent years and lists some of her favorite targets and indications.

He describes how PARP inhibitors were initial successes and where the field is going now beyond PARP with new targets.

Tyler Van Buren discusses recent news from Acelyrin and Rocket Pharma, and comments on Moderna, BridgeBio, Iovance, and Allogene.

Ferdinandos Skoulidis describes improvements being made to G12C inhibitors and the theoretical potential for pan-RAS inhibitors.

Ferran Prat describes what advantages MD Anderson offers to drug developers running trials, what makes a good partner, and areas of science

Ross Barrett describes how the Cancer Focus Fund provides financing, advice, and help with getting into the clinic at MD Anderson.

Dr. Heymach discusses KRAS, refined TKI matching, antibody-drug conjugates, cell therapies, and cancer vaccines.

Leslie Williams explains how harnessing tRNA might be used for nonsense mutation diseases and for marking unwanted proteins for destruction.

Brian Gallagher describes what it is like raising venture funds in biotech today and also offers areas of science that he is focused on.

Brian Skorney discusses this week’s data from Neurocrine Biosciences and Crinetics, and comments on Amgen, Regeneron, and Arbutus.

Dennis Purcell talks about the biotech downturn, what areas of science interest him going forward, and memories of Hambrecht & Quist.

Dr. Frost describes the elements needed for a city to spark biotech innovation and the progress that Miami has been making.

Evan Seigerman gives his take on biotech and the CMS list, Lilly, Amgen, Skyscraper-01, Structure Therapeutics, Disc Medicine and Replimune.

Dr. Levine talks about emerging technology trends that might improve CAR-T therapies on the six-year anniversary of the first approved CAR-T

Matt Phipps gives his take on biotech and discusses Amgen, Genmab, JNJ, Merus, Janux, Autolus, Agenus, and Ikena.

Yaron Werber gives his take on biotech and discusses Legend, 2seventy bio, Arrowhead, Stoke, argenx, Immunovant, Roivant, and Springworks.

Rep. Auchincloss discusses the IRA, PBMs, funding for basic research, and other policies that affect the biotech community in his district.

ustin Zelin gives his take on biotech and discusses Viking Therapeutics, 89bio, Syndax, Kura Oncology, Poseida, and ProKidney.

Michael Yee gives his take on biotech and discusses Vertex, Ventyx Biosciences, ALX Oncology, Akero, and Prothena.

Steve Pearson walks us through the potential demand and accessibility dynamics of these key gene therapy launches.